Download PDF
Dtsch Med Wochenschr 2015; 140(13): 982-989
DOI: 10.1055/s-0041-102453
Dossier
Multiresistente Erreger
© Georg Thieme Verlag KG Stuttgart · New York

Staphylococcus-aureus-Bakteriämie – eine eigene Entität

Staphylococcus aureus bacteremia - a distinct entity
Sebastian Weis
1   Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena
2   Center for Sepsis Control and Care, Universitätsklinikum Jena
,
Achim J. Kaasch
3   Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Köln
,
Siegbert Rieg
4   Abteilung Infektiologie, Klinik für Innere Medizin II, Universitätsklinikum Freiburg
,
Bettina Löffler
5   Institut für Medizinische Mikrobiologie, Universitätsklinikum Jena
,
Stefan Hagel
1   Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena
6   Klinik für Innere Medizin IV, Universitätsklinikum Jena
,
Christina Forstner
1   Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena
7   Klinische Abteilung für Infektionen und Tropenmedizin, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien
,
Frank M. Brunkhorst
8   Zentrum für klinische Studien, Universitätsklinikum Jena
,
Mathias W. Pletz
1   Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2015 (online)

Also available at
    Permissions and Reprints

See also:

Therapie bei Staphylococcus-aureus-Bakteriämie: Behandlung bei Penicillin-sensiblem S. aureusDtsch Med Wochenschr 2016; 141(10): 674-674
DOI: 10.1055/s-0041-108938

See also:

Therapie bei Staphylococcus-aureus-Bakteriämie: Wann welches Antibiotikum einsetzen?Dtsch Med Wochenschr 2016; 141(10): 674-674
DOI: 10.1055/s-0041-108939

Zusammenfassung

Bakteriämien verursacht durch Methicillin-sensible (MSSA) und Methicillin-resistente (MRSA) Staphylococcus aureus Stämme sind häufig komplizierte Infektionserkrankungen, die mit einer hohen Letalität assoziiert sind und aufgrund der Besonderheiten in Verlauf, Komplikationen und Therapie eine eigene Entität darstellen.

Diese Übersichtsarbeit befasst sich mit den aktuellen Empfehlungen zum Umgang mit MSSA und MRSA Bakteriämien und erklärt, warum der Einbezug eines klinischen Infektiologen das Überleben der Patienten verbessert und zum therapeutischen Standard gehören sollte.

Abstract

Bacteremia caused by Methicillin-sensitive (MSSA) and Methicillin-resistant (MRSA) Staphyloccus aureus strains are common and severe infections associated with high mortality rates and specific characteristics in disease course, complications and therapy. In this review, we discuss current recommendations for the diagnosis and treatment of MSSA and MRSA bloodstream infections. We also highlight why infectious disease consultation improves the treatment and outcome of patients with SAB and should be considered as a standard of care.

Schlüsselwörter

Staphylococcus aureus Bakteriämie - Infektion - MRSA - MSSA

Keywords

Staphylococcus aureus bacteraemia - infection - MRSA - MSSA
 

  • Literatur

  • 1 Bai AD, Showler A, Burry L et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. J Antimicrob Chemother 2015; 70: 1539-1546
    CrossrefPubMedGoogle Scholar
  • 2 Bloos F, Thomas-Ruddel D, Ruddel H et al. Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study. Crit Care 2014; 18: R42
    CrossrefPubMedGoogle Scholar
  • 3 Bodmann KF, Grabein B. Expertenkommission der PEG f. Chemotherapie. Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen Update 2010. Chemother J 2010; 19: 179-255
    PubMedGoogle Scholar
  • 4 Borde JP, Kern WV. Therapie von MRSA-Infektionen. Dtsch Med Wochenschr 2012; 137: 2553-2557
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Chan KE, Warren HS, Thadhani RI et al. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol 2012; 23: 1551-1559
    CrossrefPubMedGoogle Scholar
  • 6 Chang FY, MacDonald BB, Peacock Jr JE et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 2003; 82: 322-332
    CrossrefPubMedGoogle Scholar
  • 7 Cockerill 3rd FR, Wilson JW, Vetter EA et al. Optimal testing parameters for blood cultures. Clin Infect Dis 2004; 38: 1724-1730
    PubMedGoogle Scholar
  • 8 Coiffier G, Albert JD, Arvieux C, Guggenbuhl P. Optimizing combination rifampin therapy for staphylococcal osteoarticular infections. Joint Bone Spine 2013; 80: 11-17
    PubMedGoogle Scholar
  • 9 Corona Perez-Cardona PS, Barro Ojeda V, Rodriguez Pardo D et al. Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. J Antimicrob Chemother 2012; 67: 1749-1754
    CrossrefPubMedGoogle Scholar
  • 10 Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 53-59
    CrossrefPubMedGoogle Scholar
  • 11 Daver NG, Shelburne SA, Atmar RL et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 2007; 54: 539-544
    PubMedGoogle Scholar
  • 12 Fatkenheuer G, Kaasch AJ. How deadly is meticillin-resistant Staphylococcus aureus?. Lancet Infect Dis 2014; 14: 905-907
    CrossrefPubMedGoogle Scholar
  • 13 Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23: 14-34
    PubMedGoogle Scholar
  • 14 Forstner C, Dungl C, Tobudic S et al. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence. Clin Microbiol Infect 2013; 19: E291-E297
    CrossrefPubMedGoogle Scholar
  • 15 Fowler Jr VG, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665
    CrossrefPubMedGoogle Scholar
  • 16 Fowler Jr VG, Kong LK, Corey GR et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179: 1157-1161
    CrossrefPubMedGoogle Scholar
  • 17 Fowler Jr VG, Olsen MK, Corey GR et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 2066-2072
    CrossrefPubMedGoogle Scholar
  • 18 Friedman ND, Kaye KS, Stout JE et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791-797
    CrossrefPubMedGoogle Scholar
  • 19 Fuster D, Tomas X, Mayoral M et al. Prospective comparison of whole-body (18)F-FDG PET / CT and MRI of the spine in the diagnosis of haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging 2015; 42: 264-271
    CrossrefPubMedGoogle Scholar
  • 20 Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol 2009; 17: 59-65
    CrossrefPubMedGoogle Scholar
  • 21 Habib G, Hoen B, Tornos P et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30: 2369-2413
    Google Scholar
  • 22 Harbarth S, von Dach E, Pagani L et al. Randomized non-inferiority trial to compare trimethoprim / sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. J Antimicrob Chemother 2015; 70: 264-272
    CrossrefPubMedGoogle Scholar
  • 23 Heriot G, Yeoh J, Street A et al. Echocardiography has minimal yield and may not be warranted in Staphylococcus aureus bacteremia without clinical risk factors for endocarditis. Eur J Clin Microbiol Infect Dis 2015; 34: 1231-1236
    CrossrefPubMedGoogle Scholar
  • 24 Holland TL, Arnold C, Fowler Jr VG. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014; 312: 1330-1341
    CrossrefPubMedGoogle Scholar
  • 25 Holmes NE, Howden BP. What’s new in the treatment of serious MRSA infection?. Curr Opin Infect Dis 2014; 27: 471-478
    CrossrefPubMedGoogle Scholar
  • 26 Holmes NE, Tong SY, Davis JS, Hal SJ. Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond. Semin Respir Crit Care Med 2015; 36: 17-30
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Honda H, Krauss MJ, Jones JC et al. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123: 631-637
    CrossrefPubMedGoogle Scholar
  • 28 Jensen AG. Importance of focus identification in the treatment of Staphylococcus aureus bacteraemia. J Hosp Infect 2002; 52: 29-36
    CrossrefPubMedGoogle Scholar
  • 29 Jensen AG, Wachmann CH, Espersen F et al. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 2002; 162: 25-32
    CrossrefPubMedGoogle Scholar
  • 30 Kaasch AJ, Barlow G, Edgeworth JD et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect 2014; 68: 242-251
    PubMedGoogle Scholar
  • 31 Kaasch AJ, Fowler Jr VG, Rieg S et al. Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis 2011; 53: 1-9
    CrossrefPubMedGoogle Scholar
  • 32 Kaasch AJ, Rieg S, Hellmich M et al. Differential time to positivity is not predictive for central line-related Staphylococcus aureus bloodstream infection in routine clinical care. J Infect 2014; 68: 58-61
    CrossrefPubMedGoogle Scholar
  • 33 Kaasch AJ, Rieg S, Kuetscher J et al. Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study. Infection 2013; 41: 979-985
    CrossrefPubMedGoogle Scholar
  • 34 Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis 2010; 23: 346-358
    CrossrefPubMedGoogle Scholar
  • 35 Kern WV. Umstrittene Therapieempfehlungen für die infektiöse Endokarditis. Internist 2013; 54: 1087-1088
    CrossrefPubMedGoogle Scholar
  • 36 Kim SH, Kim KH, Kim HB et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52: 192-197
    CrossrefPubMedGoogle Scholar
  • 37 Kouijzer IJ, Vos FJ, Janssen MJ et al. The value of 18F-FDG PET / CT in diagnosing infectious endocarditis. Eur J Nucl Med Mol Imaging 2013; 40: 1102-1107
    CrossrefPubMedGoogle Scholar
  • 38 Laupland KB, Lyytikainen O, Sogaard M et al. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. Clin Microbiol Infect 2013; 19: 465-471
    CrossrefPubMedGoogle Scholar
  • 39 Lenz R, Leal JR, Church DL et al. The distinct category of healthcare associated bloodstream infections. BMC Infect Dis 2012; 12: 85
    CrossrefPubMedGoogle Scholar
  • 40 Leonard SN. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic / pharmacodynamic model. PLoS One 2012; 7: e42103
    CrossrefPubMedGoogle Scholar
  • 41 Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-292
    CrossrefPubMedGoogle Scholar
  • 42 Liu GY, Essex A, Buchanan JT et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med 2005; 202: 209-215
    CrossrefPubMedGoogle Scholar
  • 43 Lopez-Cortes LE, Del Toro MD, Galvez-Acebal J et al. Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57: 1225-1233
    CrossrefPubMedGoogle Scholar
  • 44 Mitchell DH, Howden BP. Diagnosis and management of Staphylococcus aureus bacteraemia. Intern Med J 2005; 35 (Suppl. 02) S17-S24
    CrossrefPubMedGoogle Scholar
  • 45 Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis 2009; 48 (Suppl. 04) S231-S237
    CrossrefPubMedGoogle Scholar
  • 46 Palraj BR, Baddour LM, Hess EP et al. Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia. Clin Infect Dis 2015; DOI: 10.1093/cid/civ235.
    PubMedGoogle Scholar
  • 47 Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? – Comparison of pharmacology and clinical efficacy. Eur J Med Res 2010; 15: 507-513
    CrossrefPubMedGoogle Scholar
  • 48 Proctor RA, von Eiff C, Kahl BC et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4: 295-305
    CrossrefPubMedGoogle Scholar
  • 49 Riedel S, Bourbeau P, Swartz B et al. Timing of specimen collection for blood cultures from febrile patients with bacteremia. J Clin Microbiol 2008; 46: 1381-1385
    CrossrefPubMedGoogle Scholar
  • 50 Rieg S, Kern WV. Die nosokomiale Staphylococcus aureus-Bakteriämie. Krankenhaushygiene up2date 2011; 6: 261-272
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Rieg S, Peyerl-Hoffmann G, de With K et al. Mortality of S. aureus bacteremia and infectious diseases specialist consultation – a study of 521 patients in Germany. J Infect 2009; 59: 232-239
    CrossrefPubMedGoogle Scholar
  • 52 Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2013. Robert Koch-Institut; 2014
    Google Scholar
  • 53 Roberts JA, Taccone FS, Udy AA et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011; 55: 2704-2709
    CrossrefPubMedGoogle Scholar
  • 54 Rubinstein E. Staphylococcus aureus bacteraemia with known sources. Int J Antimicrob Agents 2008; 32 (Suppl. 01) S18-20
    CrossrefPubMedGoogle Scholar
  • 55 Schmitt S, McQuillen DP, Nahass R et al. Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. Clin Infect Dis 2014; 58: 22-28
    CrossrefPubMedGoogle Scholar
  • 56 Schmitz RP, Keller PM, Baier M et al. Quality of blood culture testing – a survey in intensive care units and microbiological laboratories across four European countries. Crit Care 2013; 17: R248
    CrossrefPubMedGoogle Scholar
  • 57 Schweizer ML, Furuno JP, Harris AD et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 2011; 11: 279
    CrossrefPubMedGoogle Scholar
  • 58 Seifert H, Abele-Horn M, Fätkenheuer G et al. MiQ Blutkulturdiagnostik Sepsis, Endokarditis, Katheterinfektionen, Teil I. Müchen: Elsevier; 2007
    Google Scholar
  • 59 Seifert H, Wisplinghoff H, Kaasch A et al. Epidemiologie, Verlauf und Prognose der Staphylococcus-aureus-Bakteriämie – Erste Ergebnisse der INSTINCT-Kohorte. Dtsch Med Wochenschr 2008; 133: 340-345
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Sinha B, Herrmann M. Mechanism and consequences of invasion of endothelial cells by Staphylococcus aureus. Thromb Haemost 2005; 94: 266-277
    PubMedGoogle Scholar
  • 61 Stratton CW, Liu C, Weeks LS. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. Antimicrob Agents Chemother 1987; 31: 1210-1215
    CrossrefPubMedGoogle Scholar
  • 62 Tuchscherr L, Heitmann V, Hussain M et al. Staphylococcus aureus small-colony variants are adapted phenotypes for intracellular persistence. J Infect Dis 2010; 202: 1031-1040
    CrossrefPubMedGoogle Scholar
  • 63 Tuchscherr L, Medina E, Hussain M et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 2011; 3: 129-141
    CrossrefPubMedGoogle Scholar
  • 64 van Hal SJ, Jensen SO, Vaska VL et al. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev 2012; 25: 362-386
    CrossrefPubMedGoogle Scholar
  • 65 Vogel M, Schmitz RP, Hagel S et al. Impact of infectious diseases specialists consultation on the management andoutcomes of Staphylococcus aureus bacteremia – a systematic review and metaanalysis. Kopenhagen: Poster Abstract ECCMID Annual Meeting 2015
    PubMedGoogle Scholar
  • 66 Vos FJ, Kullberg BJ, Sturm PD et al. Metastatic infectious disease and clinical outcome in Staphylococcus aureus and Streptococcus species bacteremia. Medicine 2012; 91: 86-94
    CrossrefPubMedGoogle Scholar
  • 67 Weidenmaier C, Goerke C, Wolz C. Staphylococcus aureus determinants for nasal colonization. Trends Microbiol 2012; 20: 243-250
    CrossrefPubMedGoogle Scholar
  • 68 Westphal N, Plicht B, Naber C. Infective endocarditis – prophylaxis, diagnostic criteria, and treatment. Dtsch Arztebl Int 2009; 106: 481-489; quiz 490
    PubMedGoogle Scholar
  • 69 Yaw LK, Robinson JO, Ho KM. A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study. Lancet Infect Dis 2014; 14: 967-975
    CrossrefPubMedGoogle Scholar